Nanozyme-based biosensing for clinical diagnosis of COVID-19: A mini review

TL;DR

This review discusses nanozyme-based biosensing techniques that offer rapid, accurate, and cost-effective alternatives for COVID-19 diagnosis, overcoming limitations of traditional methods like PCR and CT scans.

Contribution

It provides an overview of recent advances in nanozyme-based diagnostic methods for COVID-19, highlighting their potential for early and reliable detection.

Findings

Nanozyme sensors enable rapid COVID-19 detection.

Colorimetric and fluorescence-based nanozyme methods improve accuracy.

Nanozymes offer a promising platform for point-of-care diagnostics.

Abstract

Several clinical methods had been utilized for diagnosis of COVID-19 for instance, real-time reverse transcription-polymerase chain reaction (rRT-PCR), hematology examination, polymerase chain reaction (PCR), diagnostic guidelines based on clinical features, and Chest CT scans. However, the accurate current methods are time-consuming and expensive and other methods are inaccurate. To solve these drawbacks, nanozyme-based sensors have been developed for the reliable, accurate, and rapid detection of SARS-CoV-2. The main basis of these sensors is the detection of color variation of a nanozyme-mediated oxidation reaction in the presence and the absence of antigens of COVID-19. Besides, some of methods are based on probing the fluorescence of these systems as the clinical signal toward detection of SARS-CoV-2. This mini review focused on overviewing the nanozymes-based methods toward COVID-19 diagnosis. The historical background of COVID-19 was reviewed. Thereafter, the biomedical applications of nanozymes was discussed and finally, the recent progress of early diagnosis of COVID-19 based on nanozymatic systems was briefly reviewed.